- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01749540
Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia
December 13, 2016 updated by: Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With Beta-Thalassemia Intermedia
The purpose of this study is to evaluate the effects of ACE-536 in patients with beta-thalassemia.
Study Overview
Detailed Description
To evaluate the proportion of β-thalassemia patients who have an erythroid response, defined as:
- a hemoglobin increase of ≥ 1.5 g/dL from baseline for ≥ 14 days (in the absence of red blood cell [RBC] transfusions) in non-transfusion dependent patients, or
- ≥ 20% reduction in RBC transfusion burden compared to pretreatment in transfusion dependent patients.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Athens, Greece
- Laiko General Hospital, Ampelokipi
-
-
-
-
-
Brindisi, Italy
- Ospedale "A. Perriino" U.O Ematologia
-
Catania, Italy
- ARNAS Garibaldi - P.O. Garibaldi Centro
-
Ferrara, Italy
- A.O.U. Arcispedale S. Anna
-
Modena, Italy
- CEMEF Medicina 2
-
Napoli, Italy
- AORN A. Cardarelli
-
Napoli, Italy
- A.O.U. Seconda Università degli Studi di Napoli
-
Orbassano, Italy
- A.O.U. San Luigi Gonzaga
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Men or women >=18 years of age
- For the dose escalation phase of the study: documented diagnosis of β-thalassemia intermedia (transfusion dependent patients must not have begun regular transfusions at age < 4.0 years). For the expansion cohort: documented diagnosis of β-thalassemia (including β-thalassemia major or β-thalassemia intermedia).
- Prior splenectomy or spleen size < 18 cm in the longest diameter by abdominal ultrasound (dose escalation cohorts only).
- Anemia, defined as: (i) mean hemoglobin concentration < 10.0 g/dL of 2 measurements (one performed within one day prior to Cycle 1 Day 1 and the other performed during the screening period [Day -28 to Day -1]) in non-transfusion dependent patients, defined as having received < 4 units of RBCs within 8 weeks prior to Cycle 1 Day 1, or (ii) transfusion dependent, defined as requiring ≥ 4 units of RBCs every 8 weeks (confirmed over 6 months prior to Cycle 1 Day 1).
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN).
- Serum creatinine ≤ 1.5 x ULN.
- Adequate pregnancy avoidance measures.
- Patients are able to adhere to the study visit schedule, understand and comply with all protocol requirements.
- Understand and able to provide written informed consent.
Key Exclusion Criteria:
- Any clinically significant pulmonary (including pulmonary hypertension), cardiovascular, endocrine, neurologic, hepatic, gastrointestinal, infectious, immunological (including clinically significant allo- or auto-immunization) or genitourinary disease considered by the investigator as not adequately controlled prior to Cycle 1 Day 1.
- Folate deficiency.
- Symptomatic splenomegaly.
- Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B (HBV) or active infectious hepatitis C (HCV).
- Known history of thromboembolic events ≥ grade 3 according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4.0 (current active minor version).
- Ejection fraction < 50% by echocardiogram, MUGA or cardiac MRI.
- Uncontrolled hypertension defined as systolic blood pressure (BP) ≥ 150 mm Hg or diastolic BP ≥ 95 mm Hg.
- Heart failure class 3 or higher (New York Heart Association, NYHA).
- QTc > 450 msec on screening ECG.
- Platelet count < 100 x10(9)/L or > 1,000 x10(9)/L.
- Proteinuria ≥ Grade 2.
- Any active infection requiring parenteral antibiotic therapy within 28 days prior to Cycle 1 Day 1 or oral antibiotics within 14 days of Cycle 1 Day 1.
- Treatment with another investigational drug or device, or approved therapy for investigational use ≤ 28 days prior to Cycle 1 Day 1, or if the half-life of the previous investigational product is known, within 5 times the half-life prior to Cycle 1 Day 1, whichever is longer.
- Transfusion event within 7 days prior to Cycle 1 Day 1.
- Patients receiving or planning to receive hydroxyurea treatment. Patients must not have had hydroxyurea within 90 days of Cycle 1 Day 1.
- Splenectomy within 56 days prior to Cycle 1 Day 1.
- Major surgery (except splenectomy) within 28 days prior to Cycle 1 Day 1. Patients must have completely recovered from any previous surgery prior to Cycle 1 Day 1.
- Iron chelation therapy initiated within 56 days prior to Cycle 1 Day 1.
- Cytotoxic agents, systemic corticosteroids, immunosuppressants, or anticoagulant therapy such as warfarin or heparin within 28 days prior to Cycle 1 Day 1 (prophylactic aspirin up to 100 mg/d is permitted).
- Pregnant of lactating females.
- History of severe allergic or anaphylactic reactions of hypersensitivity to recombinant proteins or excipients in the investigational drug.
- Prior treatment with sotatercept (ACE-011) or ACE-536.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACE 536
ACE-536 - 1 of 7 possible dose levels.
|
Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who have an erythroid response.
Time Frame: Assessed at approximately 24 weeks from patient screening.
|
Proportion of patients who have an erythroid response, defined as a 1) a hemoglobin increase of ≥ 1.5 g/dL from baseline for ≥ 14 days (in the absence of red blood cell [RBC] transfusions) in non-transfusion dependent patients, or 2) ≥ 20% reduction in RBC transfusion burden compared to pretreatment in transfusion dependent patients.
|
Assessed at approximately 24 weeks from patient screening.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events.
Time Frame: From treatment initiation to End-of-Study visit (approximately 24 weeks later).
|
From treatment initiation to End-of-Study visit (approximately 24 weeks later).
|
Change in hemoglobin level in non-transfusion dependent patients.
Time Frame: Baseline to approximately 24 weeks.
|
Baseline to approximately 24 weeks.
|
Changes in biomarkers of erythropoiesis, hemolysis, iron metabolism and bone metabolism.
Time Frame: Baseline to approximately 24 weeks.
|
Baseline to approximately 24 weeks.
|
ACE-536 pharmacokinetics.
Time Frame: Measured at multiple time points over the course of treatment, from study day 1 to approximately 24 weeks.
|
Measured at multiple time points over the course of treatment, from study day 1 to approximately 24 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman ML, Attie KM. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia. Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7.
- Cappellini MD, Taher AT. The use of luspatercept for thalassemia in adults. Blood Adv. 2021 Jan 12;5(1):326-333. doi: 10.1182/bloodadvances.2020002725.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
December 10, 2012
First Submitted That Met QC Criteria
December 12, 2012
First Posted (Estimate)
December 13, 2012
Study Record Updates
Last Update Posted (Estimate)
December 14, 2016
Last Update Submitted That Met QC Criteria
December 13, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A536-04
- 2012-002499-15 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-Thalassemia
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)RecruitingSickle Cell Disease | Sickle B+ Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Hemoglobin CUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedSickle Cell Disease | Sickle B+ Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Hemoglobin CUnited States
-
University of California, San FranciscoRecruitingAlpha-Thalassemia | Alpha Thalassemia Major | Alpha Thalassemia MinorUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingSickle Cell Disease | Sickle B+ Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Hemoglobin CUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedSickle Cell Disease | Sickle B+ Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Hemoglobin CUnited States
-
Agios Pharmaceuticals, Inc.Active, not recruitingTransfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Bulgaria, United Kingdom, Turkey, Italy, Greece, United Arab Emirates, Brazil, Denmark, Lebanon, Saudi Arabia
-
Agios Pharmaceuticals, Inc.Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United Kingdom, Malaysia, United States, Netherlands, Bulgaria, Turkey, Italy, Canada, Brazil, France, United Arab Emirates, Denmark, Greece, Lebanon, Saudi Arabia
-
University of California, San FranciscoCalifornia Institute for Regenerative Medicine (CIRM)Enrolling by invitationHemoglobinopathies | Alpha Thalassemia Major | Thalassemia Major | Fetal Hydrops | Hemoglobinopathy; With Thalassemia | Fetal Anemia | Alpha; Thalassemia | Thalassemia Alpha | A-ThalassemiaUnited States
Clinical Trials on ACE-536
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic SyndromesUnited States
-
CelgeneActive, not recruitingMyelodysplastic SyndromesChina, Japan
-
CelgeneCompletedPrimary Myelofibrosis | AnemiaUnited States, France, Italy, United Kingdom
-
CelgeneAcceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...CompletedBeta-Thalassemia | Erythrocyte TransfusionUnited States, Israel, Australia, Turkey, Taiwan, Malaysia, United Kingdom, Canada, Thailand, France, Lebanon, Italy, Bulgaria, Greece, Tunisia
-
CelgeneAcceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...CompletedMyelodysplastic SyndromesCanada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbRecruitingMyelodysplastic Syndromes | Anemia | Myeloproliferative NeoplasmUnited States
-
Bristol-Myers SquibbRecruiting
-
CelgeneAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...RecruitingBeta-ThalassemiaUnited States, Turkey, Italy, Thailand, Germany, Greece